InflammaSense Named Performer on ARPA-H CIRCLE Award for Real-Time Immune Monitoring

InflammaSense, a California-based pre-revenue medtech company developing wearable autonomic neurography (ANG) technology, has announced its selection as a performer on an Advanced Research Projects Agency for Health (ARPA-H) CIRCLE program receiving up to $38 million to transform how clinicians track and treat critical illness in intensive care units. InflammaSense joins the program as a subaward performer under prime awardee the University of Vermont, working alongside Gary An on the ReSCUED effort within CIRCLE.
ARPA-H’s CIRCLE program, short for Critical Illness Immunological Reprogramming and Control Point Learning Engine, targets the immune dysregulation that drives organ failure in critically ill patients, with sepsis accounting for a substantial share of the roughly 4.6 million Americans who face potentially fatal critical illness each year. The program follows a measure-model-modulate framework: compiling real-time datasets on immune and inflammatory trajectories, building patient-specific computational models, and testing interventions that target immune control points before organ failure progresses.
Under the subaward, InflammaSense will deploy its VITALx-patch, a non-invasive wearable sensor, to measure autonomic and inflammatory signatures in up to 200 severely critically ill patients across three clinical sites. Data will feed the company’s Autonomic Research Core cascade-endotyping classifier, which stratifies patients by immune trajectory and supports the CIRCLE program’s digital-twin modeling of critical illness. The work builds on InflammaSense’s core platform, built on UC San Diego-owned intellectual property covering neural signal detection of immune responses through cervical autonomic neurography measured with ventral cervical or anterior neck magnetoneurography and electroneurography.
Imanuel Lerman, MD, MSc, CEO and Founder of InflammaSense, said CIRCLE gives the company a path to validate ANG at scale in the population it was designed to serve. Lerman noted that sepsis hyperimmune and immunoparalysis states are difficult to detect in real time with existing tools, and that this program will systematically determine whether continuous, non-invasive autonomic neurography monitoring can reliably flag that window early enough to act on it.
